Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme

A robust body of evidence supports the concept that phosphodiesterase 10A (PDE10A) activity in the basal ganglia orchestrates the control of coordinated movement in human subjects. Although human mutations in the PDE10A gene manifest in hyperkinetic movement disorders that phenocopy many features of...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 117; no. 1; pp. 677 - 688
Main Authors Tejeda, Gonzalo S., Whiteley, Ellanor L., Deeb, Tarek Z., Bürli, Roland W., Moss, Stephen J., Sheridan, Eamonn, Brandon, Nicholas J., Baillie, George S.
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 07.01.2020
Subjects
Online AccessGet full text
ISSN0027-8424
1091-6490
1091-6490
DOI10.1073/pnas.1916398117

Cover

More Information
Summary:A robust body of evidence supports the concept that phosphodiesterase 10A (PDE10A) activity in the basal ganglia orchestrates the control of coordinated movement in human subjects. Although human mutations in the PDE10A gene manifest in hyperkinetic movement disorders that phenocopy many features of early Huntington’s disease, characterization of the maladapted molecular mechanisms and aberrant signaling processes that underpin these conditions remains scarce. Recessive mutations in the GAF-A domain have been shown to impair PDE10A function due to the loss of striatal PDE10A protein levels, but here we show that this paucity is caused by irregular intracellular trafficking and increased PDE10A degradation in the cytosolic compartment. In contrast to GAF-A mutants, dominant mutations in the GAF-B domain of PDE10A induce PDE10A misfolding, a common pathological phenotype in many neurodegenerative diseases. These data demonstrate that the function of striatal PDE10A is compromised in disorders where disease-associated mutations trigger a reduction in the fidelity of PDE compartmentalization.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Edited by Joseph A. Beavo, University of Washington School of Medicine, Seattle, WA, and approved November 20, 2019 (received for review October 15, 2019)
1Present address: Department of Neurology, University of California, San Francisco, CA, 94158.
2Present address: Jnana Therapeutics, Boston, MA 02210.
Author contributions: G.S.T., E.S., N.J.B., and G.S.B. conceived the study; G.S.T., E.L.W., T.Z.D., R.W.B., S.J.M., E.S., N.J.B., and G.S.B. designed research; G.S.T., E.L.W., T.Z.D., and R.W.B. performed experiments and analyzed data; G.S.T., N.J.B., and G.S.B. wrote the paper with input from all authors.
ISSN:0027-8424
1091-6490
1091-6490
DOI:10.1073/pnas.1916398117